Find a study
Browse recruiting studies near you — free to check, always your choice.
83 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- COPD (chronic lung disease)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Testing two doses of a medicine versus placebo for COPD symptoms
📍 Research Site · Birmingham, AL · +39 more US sites · Get directions →
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- COPD (chronic lung disease)
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Testing how a genetic change in alpha-1 antitrypsin affects immune and lung responses to a pneumonia
📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
- Dementia / Alzheimer'sParkinson's disease
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson
📍 Domino's Farms · Ann Arbor, MI · Get directions →
The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.
- Parkinson's disease
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems
📍 U LLC Headquarters · Cleveland, OH · Get directions →
This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.
- Parkinson's disease
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Testing whether a low-dose seizure medicine can help Parkinson’s psychosis
📍 Johns Hopkins · Baltimore, MD · Get directions →
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.
- Parkinson's disease
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result
📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
- Parkinson's disease
A Study of Buntanetap in Participants With PD
Testing the long-term safety of buntanetap in people with Parkinson’s
📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.
- Dementia / Alzheimer'sParkinson's disease
PET Imaging Evaluation of [11C]SY08
Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s
📍 MGH · Charlestown, MA · Get directions →
The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.
- COPD (chronic lung disease)Asthma
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
Testing whether positive airway pressure helps a lung medicine (NAC) reach mucus plugs in asthma or
📍 UCSF Airway Clinical Research Center · San Francisco, CA · Get directions →
The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.
- Parkinson's disease
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
Testing an injection for brain scans to study Parkinson’s disease and safety
📍 Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT · Get directions →
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study.
- Parkinson's disease
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s
📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
- COPD (chronic lung disease)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Testing two doses of a daily medicine versus placebo in people with COPD over 52 weeks
📍 DM Clinical Research - Phoenix · Phoenix, AZ · +11 more US sites · Get directions →
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
- Type 2 diabetesHeart / cardiovascular disease
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
Testing how drinking ketone drinks affects heart function in people with type 2 diabetes and heart
📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.
- Parkinson's disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
Testing a new PET brain scan to measure nerve protein buildup in Parkinson’s
📍 Invicro (dba Perceptive) · New Haven, CT · +1 more US site · Get directions →
This clinical study is being conducted to learn more about a new imaging drug called \[18F\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.
- Heart / cardiovascular disease
Improving Coronary Vascular Health in Women
Testing whether blood flow in heart arteries can be improved in women with HIV
📍 Massachusetts General Hospital · Boston, MA · Get directions →
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.
- DepressionParkinson's disease
Imaging Depression in Parkinson's Disease
Studying brain changes linked to depression in people with Parkinson’s
📍 Yale University · New Haven, CT · Get directions →
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
- High blood pressureCOPD (chronic lung disease)
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the
📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →
The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.
- Parkinson's disease
Ketamine for Veterans With Parkinson's Disease
Testing ketamine for depression in veterans with Parkinson’s disease
📍 San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA · Get directions →
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide.
- Parkinson's disease
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
Tracking how brain scans change over time in people with early Parkinson’s
📍 Institute for Neurodegenerative Disorders · New Haven, CT · +1 more US site · Get directions →
The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months.
- DepressionParkinson's disease
Psilocybin Therapy for Depression in Parkinson's Disease
Testing whether psilocybin therapy improves depression symptoms in people with Parkinson’s disease
📍 University of California, San Francisco · San Francisco, CA · Get directions →
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
- Parkinson's disease
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions
📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
- COPD (chronic lung disease)
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
Testing an add-on treatment for adults having a COPD flare with type 2 inflammation
📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +21 more US sites · Get directions →
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
- Parkinson's disease
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Testing the safety and effect of a gene therapy put into the brain for moderate Parkinson’s disease
📍 Mayo Clinic · Phoenix, AZ · +33 more US sites · Get directions →
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
- Heart / cardiovascular diseaseLupus (SLE)
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Testing whether anifrolumab improves blood vessel risk markers in lupus
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.
- Parkinson's disease
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Testing an oral low-dose carbon monoxide liquid in people with Parkinson’s
📍 Quest Research Institute · Farmington Hills, MI · Get directions →
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
- COPD (chronic lung disease)
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Testing different doses of two inhaled medicines for COPD symptoms
📍 SEC Clinical Research, LLC · Dothan, AL · +39 more US sites · Get directions →
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
- COPD (chronic lung disease)💵 May compensate
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure
📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →
This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.
- Parkinson's disease
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
Studying how a brain imaging tracer binds in early Parkinson’s over 24 months
📍 UAB · Birmingham, AL · Get directions →
The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.
- COPD (chronic lung disease)
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
Comparing nebulizer and inhaler treatments for COPD symptoms
📍 The University of Tennessee Graduate School of Medicine · Knoxville, TN · Get directions →
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).
- Parkinson's disease
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Testing pyridostigmine as a treatment for constipation in Parkinson disease
📍 University of Vermont Medical Center · Burlington, VT · Get directions →
Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments.
- Parkinson's disease
Rehabilitation of Airway Protection in Parkinson's Disease
Testing therapy to improve airway protection problems in Parkinson’s
📍 Purdue University · West Lafayette, IN · +1 more US site · Get directions →
Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits.
- COPD (chronic lung disease)
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Testing how a study medicine affects safety and symptoms in people with COPD
📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.
- Obesity / overweightHigh blood pressureCOPD (chronic lung disease)
Feasibility of Semaglutide in Advanced Lung Disease
Testing whether semaglutide can be given safely to people with advanced lung disease
📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.
- COPD (chronic lung disease)
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Testing solrikitug in people with COPD to check safety and effects
📍 University of Alabama at Birmingham Hospital · Birmingham, AL · +39 more US sites · Get directions →
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
- Parkinson's disease
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Testing an injected cell treatment for safety in people with advanced Parkinson’s
📍 Cornell University Weill Medical College · New York, NY · Get directions →
This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
- Dementia / Alzheimer'sParkinson's disease
18F-mFBG Cardiac Uptake With Lewy Body Dementia
Testing a heart imaging tracer to see how Lewy body dementia affects nerve signals
📍 Houston Methodist Neurological Institute · Houston, TX · Get directions →
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.
- Parkinson's disease
Tenapanor in Synucleinopathy-Related Constipation
Testing tenapanor for constipation related to Parkinson’s disease
📍 Cedar Valley Digestive Health Center · Waterloo, IA · Get directions →
Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
- Parkinson's disease
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
Testing how much brain tau buildup is in people with Parkinson’s using PET scans
📍 Institute for Neurodegenerative Disorders / XingImaging, LLC · New Haven, CT · Get directions →
The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.
- Parkinson's disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Testing two doses of an add-on medicine to levodopa for Parkinson’s with motor fluctuations
📍 University of Arkansas for Medical Sciences · Little Rock, AR · +24 more US sites · Get directions →
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
- Parkinson's disease
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s
📍 Cleveland Clinic · Cleveland, OH · Get directions →
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.
- COPD (chronic lung disease)
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
Testing the right dose of a long-acting medicine for moderate to severe COPD
📍 WB Contracted Clinical Research Site · Miami Lakes, FL · +3 more US sites · Get directions →
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms.
- Obesity / overweightHeart / cardiovascular disease
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart
📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.
- Parkinson's disease
Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)
Testing an 8-week exercise program with boxing and computer games for people with Parkinson disease
📍 Equilibrium Physical Therapy · Ventura, CA · Get directions →
In this pilot study the research will explore whether exercises and the outcome measures would be acceptable to conduct a more detailed research study. This 8 week pilot study will utilize a comprehensive exercise program that includes non-contact boxing along with computerized games for individuals with Parkinson Disease.
- Parkinson's disease
Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease
Testing whether automatic speech recognition feedback improves speech clarity and social
📍 Teachers College, Columbia University · New York, NY · Get directions →
The goal of this clinical trial is to learn whether noise-augmented feedback using automatic speech recognition improves intelligibility and social participation in individuals with Parkinson's disease. The main questions the investigators will address are: Does noise-augmented feedback lead to increased intelligibility, as measured by transcription accuracy scores?
- Obesity / overweightHeart / cardiovascular disease
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Testing how semaglutide works in people with heart failure and obesity
📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.
- Parkinson's disease
rTMS to Improve Cognition in Parkinson's
Testing whether noninvasive brain stimulation can improve thinking in people with Parkinson’s
📍 Jesse Brown VA Medical Center, Chicago, IL · Chicago, IL · +1 more US site · Get directions →
The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.
- Parkinson's disease
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Comparing treatments to see which works better for hallucinations in Parkinson’s disease
📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).
- Parkinson's disease
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
Testing a wearable sensor that gives feedback for swallowing therapy in Parkinson’s
📍 Purdue University · West Lafayette, IN · Get directions →
Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head/neck and provide biofeedback to patients and adherence data to clinicians during swallow therapy.
- Parkinson's disease
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Testing varenicline to reduce falls and improve walking multitasking in Parkinson’s
📍 University of Michigan · Ann Arbor, MI · Get directions →
This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo.
- COPD (chronic lung disease)
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
Studying how sleep apnea together with COPD affects heart health
📍 UCSD Sleep Research · La Jolla, CA · Get directions →
Major progress has been made in the area of cardiovascular disease, but we believe that further progress will involve mechanistically addressing underlying respiratory causes including chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). The most common cause of death in COPD is cardiovascular, although mechanisms are unknown.
- Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD
📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
- Heart / cardiovascular disease💵 May compensate
Canagliflozin Targeting Vascular Inflammation
Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease
📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.
- Heart / cardiovascular disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Testing a medicine to see its cardiovascular effects in adults on dialysis
📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Dementia / Alzheimer'sParkinson's disease
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Studying how nerve cell loss affects thinking ups and downs in Lewy body dementia
📍 Virginia Commonwealth University · Richmond, VA · Get directions →
The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan
- Parkinson's disease
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
Testing the safety and side effects of DSP-1083 implanted in people with Parkinson’s disease
📍 University of Kentucky Medical Center · Lexington, KY · +1 more US site · Get directions →
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts.
- Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
Testing how Akkermansia gut bacteria relate to body and blood lipid changes in people with obesity
📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →
The overriding objectives of this study are: 1. Primary outcomes: 1.
- Obesity / overweightType 2 diabetesHeart / cardiovascular disease
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart
📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.
- Parkinson's disease
Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
Testing how scans after deep brain stimulation help assess Parkinson’s gait
📍 University of Minnesota · Minneapolis, MN · Get directions →
Sixty patients will be enrolled in this study who are treated for Parkinson's disease (PD) with bilateral deep brain stimulation of subthalamic nucleus (STN) or globus pallidus (GP), who have a pre- operative 7 Tesla MRI including diffusion tensor imaging for tractography and a postoperative head CT for electrode localization, and in whom at least 3 months have passed since activation of their neurostimulators, for stabilization of clinical stimulator settings. Using their MRI and CT, the investigators will construct patient-specific models of electrical current spread to neuroanatomical tar- gets surrounding the electrode.
- Parkinson's disease
Personalized Real-Time DBS and PD Mechanisms
Studying how closed-loop deep brain stimulation and levodopa affect Parkinson’s motor symptoms
📍 Cleveland Clinic · Cleveland, OH · Get directions →
A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling.
- COPD (chronic lung disease)
Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy
Comparing a lung scan that uses xenon MRI with a radioactive scan for COPD
📍 University of Virginia Health System · Charlottesville, VA · Get directions →
Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.
- Showing the first 60 of 83. Add filters or a location to narrow down.